Since mutations in theRET proto-oncogene were discovered in thyroid carcinoma 20 years ago, research has focused on determining the prevalence of these alterations, their role in disease development and potential clinical applications. In this Review, the authors discuss these findings with respect to the pathogenic, diagnostic and prognostic roles of RETin patients with papillary thyroid carcinoma and medullary thyroid carcinoma.
- Cristina Romei
- Raffaele Ciampi
- Rossella Elisei
